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The United Kingdom Turner syndrome (TS) study examined the effect on final height of 
oxandrolone 0.05 mg/kg/day (maximum dose 2.5mg) versus placebo from 9 years of age; and 
delaying ethinylestradiol induction of puberty by two years from 12 (E12) to 14 (E14) years in 
growth hormone-treated girls with TS.  The study ran from 1999 to 2013.  By 2011, 82 of 92 
participants had reached final height and an interim analysis using the Super-Imposition by 
Translation And Rotation (SITAR) model showed significant increases in final height with both 
oxandrolone and E14.  The analysis has been repeated now that all 92 patients have reached final 
height.  Oxandrolone still significantly increased final height by 4.1 cm (95% CI 1.6 to 6.6 cm, 
n=92) compared with 4.6 cm previously.  However, the E14 effect was no longer significant at 2.7 


















The United Kingdom (UK) Turner Study, conducted across the UK between 1999 and 2013, was a 
randomised, double-blind, placebo-controlled trial of growth promoting treatment in Turner 
syndrome, with an interim report published in 2011.1  The study aims were to examine the impact 
on final height of a) oxandrolone versus placebo treatment from 9 years; and b) delaying estrogen 
induction of puberty from 12 to 14 years, in girls with Turner syndrome who were receiving a 
standard dose of growth hormone.  Interim analysis showed a large effect of oxandrolone and a 
smaller effect of late pubertal induction on final height.  The purpose of the present paper is to 
report the reanalysis of the UK Turner study now that all patients have reached final height.  
 
Methods 
As reported previously1, the study protocol involved two randomisations in girls with Turner 
syndrome, confirmed on karyotype, who were receiving growth hormone (GH) in the standard 
dosage of 10mg/m2/wk, equivalent to 55 μg/kg/day).  The first randomisation at 9 years was to 
receive either oxandrolone 0.05mg/kg/day (max daily dose 2.5mg) or placebo until final height.  
The second randomisation at 12 years was for girls with serum follicle stimulating hormone levels 
> 10 u/L (reflecting significant ovarian insufficiency) to receive oestrogen in the form of 
ethinylestradiol at either 12 or 14 years.  Girls receiving ethinylestradiol at 12 years (E12) took 2 
μg daily for one year, followed by 4 μg daily for the second year, and 4-monthly increments to 6, 
8 and 10 μg during the third year.  Girls receiving ethinylestradiol at 14 years (E14) took placebo 
for 2 years until 14 years, then followed the same incremental ethinyloestradiol protocol; the 
oestrogen randomisation code was broken at 15 years to allow the introduction of progesterone 
treatment.  Girls enrolled aged >12.25 years were termed the ‘late group’ and automatically 
assigned to receive ethinylestradiol at 14 years.  The primary outcome measure was final height, 




enrolment including initial age, height SDS and breakdown of karyotype can be found in the 2011 
interim report.1   
Reanalysis of the 92 girls was carried out using an updated version of the SuperImposition by 
Translation And Rotation (SITAR) model.2  Using this shape invariant model, mean curves were 
fitted to each of the four treatment arms.  Curves for individuals are matched to the mean curve by 
shifting their curve up-down (representing body size), left-right (representing growth tempo), and 
shrinking or stretching the age scale (reflecting height velocity).   
The study had been approved previously by the Scotland A Research Ethics Committee (formerly 
Multi-centre Research Ethics Committee for Scotland) [Ref. 98/0/92] as well as by local research 
ethics committees at participating centres.  Written informed consent from parents and assent from 
the girls at enrolment had also been obtained. 
 
Results 
A flow diagram showing the outcome in the 106 girls originally enrolled and the distribution of 
the 92 girls reaching final height according to randomisation is shown in Figure 1. Following the 
interim analysis published in 2011, no further patients had withdrawn and the 10 patients who 
were still growing had now reached final height.  
For the primary randomization, 43 girls had received oxandrolone and 49 placebo.  Fifty-six girls 
then underwent second randomisation at 12 years, with 28 receiving oestrogen and 28 receiving 
placebo until 14 years.  Nineteen girls were in the late group and 17 did not require pubertal 
induction with oestrogen.   
 
Final height outcome in the 92 girls who remained in the study is shown in the Table.  Mean (SD) 




Change in final height SDS was greatest for the 24 girls receiving oxandrolone: + 0.7 SDS for 
those randomised to E14 (n=13) and + 0.6 SDS for those randomised to E12 (n=11).  
Fitted curves in the oxandrolone/placebo and E12/E14 groups are shown in Figure 2.  SITAR 
analysis showed that oxandrolone increased both size/amplitude of growth (p=0.02) and growth 
velocity (p=< 0.001).  E14 showed a near-significant delay in tempo (p=0.07) and had a negative 
effect on velocity (p=0.0005).  
Oxandrolone still showed a significantly although slightly reduced increase in final height by 4.1 
cm (95% CI 1.6 to 6.6 cm, n=92; p=0.002) compared with 4.55 cm at interim analysis.  However, 
the effect of delaying pubertal induction from 12 to 14 years was no longer significant: 2.7 cm (CI 
-0.8 to 6.1 cm, n=56; p=0.13) compared with 3.75 cm previously.  





Table Final height in 92 girls completing the UK Turner study, by treatment group.  The red box indicates final height according to the interaction 
between randomisation 1 (oxandrolone or placebo) and randomisation 2 (ethinylestradiol at 12 or 14 years).  Height standard deviation scores (Ht 
SDS) are based on the UK 1990 reference3.  Delta (Δ) height refers to the change in Ht SDS from baseline (i.e. study enrolment) to final height.  
 
Characteristics Randomised to oestrogen    
at 12 years 
Randomised to oestrogen 
at 14 years 
Late group 
(oestrogen at 14 years) 
No oestrogen needed Total 
 Oxandrolone Placebo Oxandrolone Placebo Oxandrolone Placebo Oxandrolone Placebo  
(n=11) (n=17) (n=13) (n=15) (n=9) (n=10) (n=10) (n=7) (n=92) 
Age (years) 16.1 (1.5) 16.3 (0.9) 16.8 (0.8) 17.1 (0.8) 17.1 (1.0) 17.9 (1.0) 15.1 (0.9) 15.3 (1.0) 16.5 (1.3) 
Height (cm) 154.4 (3.9) 148.1 (7.2) 154.2 (5.7) 152.4 (6.6) 155.3 (4.3) 148.9 (6.0) 151.9 (6.0) 150.3 (6.3) 151.8 (6.3) 
Ht SDS -1.3 (0.7) -2.4 (1.2) -1.5 (0.9) -1.8 (1.1) -1.3 (0.7) -2.4 (1.0) -1.4 (0.9) -1.9 (0.9) -1.8 (1.0) 






The positive effect of oxandrolone on final height in Turner syndrome is in keeping with work 
from the Netherlands4 and the USA5, although the magnitude of the effect differs between these 
studies, possibly due to differences in treatment regimen and participant characteristics6.  
Unfortunately, the subsequent European production of oxandrolone has not resumed since its 
cessation in 2008.  As a result, oxandrolone, although available through import from the USA, 
remains possible only at considerable cost, limiting its application to girls aged > 9 years in whom 
the growth response to growth hormone therapy is disappointingly low despite good compliance, 
as evidenced by high-normal IGF-1 levels.  
 
The interim analysis had suggested that delaying pubertal induction with oral ethinylestradiol from 
12 to 14 years provided significant benefit.  However, the difference of 2.7 cm found on reanalysis 
was no longer significant.  A possible explanation for the reduced effect of starting pubertal 
induction at 14 years is that the oxandrolone and oestrogen at 12 years interventions encouraged 
more accelerated growth, as shown by the SITAR analysis, and that as a result the girls in these 
treatment arms finished growing earlier, with those in the placebo arms catching up only later.  
Although late pubertal induction could have a positive effect on final height, even without 
reaching significance, there can now be little support for delaying pubertal induction beyond 12 
years.  This is because 12 years is already relatively late compared to natural processes, and there 
is now evidence for better psychosocial development7 and better uterine health8 with timely 
induction.  
Since the 92 girls in this UK Turner study reached final height, several guidelines containing  
recommendations for estrogen therapy have been published. These include the consensus 
guidelines from the 2016 Cincinnati International Turner Syndrome Meeting,9  recommendations 
from the British Society for Paediatric Endocrinology and Diabetes for pubertal induction,10 and a 




Paediatric Endocrinology. 11  All these publications recommend natural estrogen in the form of 
17β-estradiol, given by either the oral or transdermal route, rather than synthetic oral estrogen 
such as ethinylestradiol. The TSWG proposes a 3-year induction programme, usually beginning at 
11 years and detailing both tablet and matrix patch protocols which allow the delivery of 
incremental estradiol doses based on body weight.11 
In conclusion, the beneficial effect of oxandrolone on final height in Turner’s syndrome is 
confirmed.  By contrast, delaying pubertal induction beyond 12 years did not significantly 
improve final height in the final analysis of this cohort.  However, the option of delaying pubertal 
induction in girls with Turner syndrome who are diagnosed particularly late (e.g. after 12 years) in 
whom short stature is a major concern should be discussed with the family.11 (975 words) 
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Figure 1  Flow diagram of outcome in 106 girls enrolled in the UK Turner study, by treatment 
group. First randomisation to Oxandrolone or placebo is shown in red and allocation to treatment or 
not with ethinylestradiol is shown in green: second randomisation to receive ethinylestradiol or 
placebo at 12 years, treatment at 14 years in placebo group, no treatment required, and automatic 
assignment to estrogen at 14 years in girls enrolled aged ≥12.25 years (late group). Withdrawals are 
shown in white.  
 
Figure 2  SITAR fitted summary height curves by trial arm for randomisation 1 [oxandrolone vs 
placebo from 9 years] (left panel) and randomisation 2 (ethinylestradiol for pubertal induction at 12 
vs 14 years] (right panel) 
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